Cholangiocarcinoma Epidemiology Forecast 2030 by DelveInsight

Cholangiocarcinoma Epidemiology Forecast 2030 by DelveInsight

DelveInsight has launched a new report on Cholangiocarcinoma Epidemiology


Cholangiocarcinoma (CCA) also known as Biliary Tract Cancer is a rare and heterogeneous malignant neoplasm with epithelial cell origin of biliary duct and histologic and biochemical features of cholangiocyte differentiation. The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural) and sometimes may affect gall bladder.


Request for free sample copy-


The Cholangiocarcinoma Epidemiology Report covers the overview, treatment practice and forecasted epidemiology of Cholangiocarcinoma Epidemiology from 2020 to 2030


Cholangiocarcinoma Epidemiology

As per the study conducted by N Patel et al., the overall incidence of Cholangiocarcinoma from 2001 to 2015 was 1.26 per 100,000 people per year in the US. Males account for higher incidence with 50.9% cases while 49.1% cases belong to females in that study. The incidence has been shown to increase in all subpopulations and specifically at a dramatic rate for ICCA and those with distant disease at the time of diagnosis.


Key facts of the Cholangiocarcinoma Epidemiology

  • Among the EU5 countries, Germany had the highest incident population of Cholangiocarcinoma (CCA), followed by Italy and the United Kingdom. In Italy, CCA incidence was recorded to be 3.36/100,000, and CCAs accounted approximately for 3% of total primitive liver cancers.
  • DelveInsight analysis concluded that the incidence rate varied based on type specific cases and the estimates showed an increasing trend in the Intrahepatic CCA cases, while Extra hepatic CCA showed a decreasing trend or in some cases are stable
  • Among the stage-specific cases, 22.9 were localized, 36.9% were regional and 40.2% belong to the distant stage of CCA in the US


Cholangiocarcinoma Epidemiology Segmentation

  • Diagnosed incident Cases of Cholangiocarcinoma (CCA) [2017–2030]
  • Gender-Specific Diagnosed Incident Cases of Cholangiocarcinoma (CCA) [2017–2030]
  • Biomarker-Specific Diagnosed Incident Cases of ICCA [2017–2030]
  • Biomarker-Specific Diagnosed Incident Cases of ECCA [2017–2030]
  • Type-Specific Diagnosed Incident cases of Cholangiocarcinoma (CCA) [2017–2030]
  • Stage-Specific Diagnosed Incident Cases of Intrahepatic CCA [2017–2030]
  • Stage-Specific Diagnosed Incident Cases of Extrahepatic CCA [2017–2030]
  • Age-Specific Diagnosed Incident Cases of CCA [2017–2030]


Cholangiocarcinoma Prevalent Population

As per DelveInsight assessments, the market size of Cholangiocarcinoma (CCA) in the 7MM was found to USD XX million in 2017, for the study period (2017-2030). Among 7MM, United States accounts for the highest market size of Cholangiocarcinoma (CCA) in comparison with EU5 and Japan.


Request for free sample copy-


Table of content

1. Key Insights 

2. Executive Summary of Cholangiocarcinoma (CCA)

3. Cholangiocarcinoma (CCA): Disease Background and Overview

4. Patient Journey

5. Epidemiology and Patient Population

6. Treatment Algorithm, Current Treatment, and Medical Practices

7. KOL Views

8. Unmet Needs

9.  Appendix

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight


What are the reasons to buy?

The Cholangiocarcinoma (CCA) Epidemiology report will allow the user to –

  • Develop business strategies by understanding the trends shaping and driving the global Cholangiocarcinoma (CCA) market
  • Quantify patient populations in the global Cholangiocarcinoma (CCA) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Cholangiocarcinoma (CCA) therapeutics in each of the markets covered
  • Understand the magnitude of Cholangiocarcinoma (CCA) population by its epidemiology
  • The Cholangiocarcinoma (CCA) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Related Reports


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States